Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

KKura Oncology, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
K

Kura Oncology, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Fostering a Workplace Place for Innovators to Thrive
    Sep 17, 2024Kura Oncology
  • Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
    Feb 15, 2024Kura Oncology
  • PharmaVoice’s Crystal Ball: Perspectives on the financial future
    Jan 9, 2024Kura Oncology
  • Kathy Ford, R.N., B.S.N., Kura COO, on Ordinarily Extraordinary – Conversations with Women in STEM podcast
    Dec 21, 2023Kura Oncology
  • Dr. Erba discusses the KOMET-001 Phase 1b safety and tolerability data of ziftomenib, a menin inhibitor, for patients with R/R NPM1-m AML
    Dec 21, 2023Kura Oncology
  • Dr. Erba offers insight into the KOMET-007 Phase 1 trial and rationale for investigating ziftomenib in combination with standards of care for the treatment of patients with newly diagnosed or R/R NPM1-m or KMT2A-r AML
    Dec 20, 2023Kura Oncology
  • Dr. Erba explains the different combinations KOMET-008 will evaluate and how it differs from KOMET-007
    Dec 19, 2023Kura Oncology
  • “Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD
    Dec 18, 2023Kura Oncology
  • Dr. Erba provides an overview of the KOMET clinical trial program
    Dec 17, 2023Kura Oncology
  • Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place
    Dec 1, 2023Kura Oncology
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions